This is a skin condition that causes firm, yellow bumps or patches, often around the eyes. It's sometimes linked to other health issues like a high white blood cell count and certain types of immune system problems. Doctors might need to check for these other issues.
Every report comes from a Lived member, sent anonymously.
Have you tried IVIG for Necrobiotic Xanthogranuloma?
Necrobiotic xanthogranuloma (NXG) is a rare, long-lasting skin disease in which clusters of immune cells collect under the skin and form firm, yellow to orange bumps and plaques. The lesions most often appear around the eyes, though they can also develop on the face, trunk and limbs. Many cause no discomfort at first, but some become painful or itchy, and over time they can thin the skin, break open into sores and leave scars. NXG matters beyond the skin because it is closely tied to the blood. Roughly 8 in 10 people with NXG have a monoclonal protein (also called a paraprotein), an abnormal antibody made in excess by a single group of plasma cells in the bone marrow. About 1 in 7 have multiple myeloma, a cancer of those plasma cells. NXG can also affect the eye socket and, less often, internal organs. Doctors classify it as a non-Langerhans cell histiocytosis, a family of disorders driven by immune cells called histiocytes.
The cause of NXG is not known. Its strong link with monoclonal proteins has led researchers to suspect that the abnormal antibody plays a role, possibly by binding fats in the blood and provoking an inflammatory reaction in the skin, but this has not been proven. The main risk factor is having a plasma cell disorder, most often monoclonal gammopathy of undetermined significance (MGUS), a usually stable condition in which a monoclonal protein is present without cancer, or multiple myeloma. Most people are diagnosed around age 60, and the condition is not linked to anything a person did or could have avoided.
NXG is usually recognized by a dermatologist and confirmed with a skin biopsy, in which a small sample is examined under a microscope. The biopsy shows a typical pattern of damaged tissue surrounded by fat-laden immune cells and giant cells, which helps separate NXG from conditions that can look similar. Xanthelasma, the common yellow cholesterol deposits on the eyelids, is the most frequent look-alike, and others include necrobiosis lipoidica, granuloma annulare and sarcoidosis. Early lesions can be hard to distinguish, so a second biopsy is sometimes needed. Because NXG is so closely linked to plasma cell disorders, blood and urine tests that look for a monoclonal protein are a central part of the workup. If one is found, a hematologist (a blood specialist) usually evaluates whether it is MGUS or myeloma, which may include a bone marrow biopsy. Experts have proposed that NXG be diagnosed when typical skin findings and a matching biopsy occur together with either a monoclonal protein or blood cancer, or lesions around the eyes. An eye examination, and sometimes imaging of the eye socket, checks for involvement there.
There is no standard treatment for NXG and no formal guidelines. Because the disease is rare, what is known comes from case reports and small series rather than controlled trials, so reported success rates may look better than what a given person can expect. Treatment is usually shared between a dermatologist and a hematologist, and an eye specialist when the eyes are involved. The treatments with the best reported results are intravenous immunoglobulin (IVIG) and corticosteroids. IVIG is an infusion of antibodies collected from donated blood, given through a vein in repeated cycles, and it calms the immune response. In published cases about 4 in 5 people improved with it. It is generally well tolerated, with headache being the most common problem, but it is expensive, used off-label for NXG, and lesions can return when it stops. Corticosteroids such as prednisone, taken by mouth or injected directly into lesions, can also help; long-term use by mouth carries well-known risks such as bone thinning, high blood sugar and weight gain, which limits how long they are used. When NXG occurs with multiple myeloma, treating the cancer comes first and can also control the skin. Myeloma medicines such as lenalidomide or thalidomide, usually combined with the steroid dexamethasone, have helped some people with a monoclonal protein even without myeloma. Antimalarial medicines and chemotherapy are other options. Improvement in the skin does not always match changes in the blood protein, so the two are tracked separately. Surgery to remove lesions is generally avoided because they often come back, except when a lesion threatens vision.
NXG tends to be chronic and slowly progressive, with periods of improvement and worsening. Many people need treatment over the long term, and finding an approach that works can take time and several attempts. No feature of the skin disease reliably predicts how it will behave in a particular person. Lesions on the face can affect appearance and comfort, and healed areas may leave thinning skin or scars. Ongoing follow-up is a core part of living with NXG. Because MGUS can progress to multiple myeloma years after the skin lesions first appear, regular blood tests with a hematologist continue even when the skin is quiet. People with eye involvement also need regular eye checks.
See a dermatologist if you develop firm yellow or orange patches or bumps around the eyes or elsewhere that persist or spread, especially if you already know you have a monoclonal protein. Contact your care team if lesions start to break open into sores, grow quickly or become more painful, since this can signal a change in the underlying blood disorder and warrants re-evaluation. Contact your care team right away about new bulging of an eye, double vision or any change in vision, because NXG in the eye socket can threaten sight.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Necrobiotic Xanthogranuloma is like, what's helped you, or ask the community a question.